News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.

Al's Comment:

 This study says that for glioblastoma patients with unmethylated MGMT, adding Temodar to radiation does not improve survival or progression free survival.    This is a retrospective study that does not control for other factors, but it is interesting. It opens the door for experimenting with other treatments for newly diagnosed MGMT unmethylated patients, such as perhaps substituting Val-083 instead of Temodar.


Posted on: 05/24/2018

. Clin Neurol Neurosurg. 2018 May 16;170:127-131. doi: 10.1016/j.clineuro.2018.05.014. [Epub ahead of print]

Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.

Lee A1, Malakhov N2, Sheth N3, Wang A4, Han P2, Schreiber D5.
 
Author information:
 
1
    Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA; Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, NY, USA. Electronic address: anna.lee@downstate.edu.
2
    Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
3
    Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA; Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, NY, USA.
4
    Department of Neurosurgery, New York Medical College, Westchester, NY, USA.
5
    Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA; Summit Medical Group MD Anderson Cancer Center, Berkeley Heights, NJ, USA.
 
Abstract
OBJECTIVE:
 
The recommended treatment for O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM) is radiation therapy with concurrent/adjuvant temozolomide (TMZ). However, it is well known that the clinical benefit from TMZ is lower in these patients. We sought to analyze patterns of care and outcomes of chemoradiation versus radiation alone in this cohort using a large, hospital database.
PATIENTS AND METHODS:
 
Patients diagnosed with MGMT promoter unmethylated GBM from 2010 to 2012 who received radiation (RT) or chemoradiation (CRT) were identified in the National Cancer Database. Logistic regression was performed to assess for predictors of receiving chemoradiation. The Kaplan-Meier method was used to assess overall survival (OS) by treatment group and Cox regression analysis was used to assess impact of covariates on OS.
RESULTS:
 
There were 738 patients who met the study criteria, of which 107 (14.5%) received RT alone and 631 (85.5%) received CRT with median RT dose 6000cGy for both groups. Median follow up for living patients was 21.9 months. Ninety-two (12.5%) patients did not undergo any resection, 330 (44.7%) underwent a subtotal resection and 316 (42.8%) had a gross total resection. The median and 2-year OS was 16.8 months and 24.7% for RT alone compared to 15.6 months and 25.9% for the CRT group (p?=?0.250). On multivariable analysis, the addition of chemotherapy had no impact on survival (HR 1.12, 95% CI 0.86-1.46, p?=?0.396).
CONCLUSION:
 
Despite the routine use of chemoradiation among patients with MGMT promoter unmethylated GBM, there does not appear to be a survival benefit compared to radiation alone.
 
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 29777945
Similar articles
Icon for Elsevier Science

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740